从2023年12月形成初稿，到根据专家反馈不断进行修改完善，直至2024年7月终稿评审通过，每一步都凝聚了编制组成员 ... 法》、《生物制品中 DNase 残留检测-核酸荧光底物法》和《生物制品中 RNase 残留检测-核酸荧光底物法》三项团体标准，就 dsRNA 定量检测、DNase ...

近日，国家药品监督管理局疫苗及生物制品质量监测与评价重点实验室与武汉瀚海新酶生物科技有限公司共同制定了《mRNA 疫苗及药物中 dsRNA 杂质定量检测-ELISA 法》、《生物制品中 DNase 残留检测-核酸荧光底物法》和《生物制品中 RNase 残留检测-核酸荧光底物法 ...

R&D Expenses: Research and development expenses for the year ended December 31, 2024 decreased to approximately $2,044,000 ...

iOS 11.3, up to iPadOS 17.6.1 ...

Single-Molecule Footprinting reveals that RNA polymerase II (Pol II) occupancy is infrequent at mouse promoters. This results ...

Q4 2024 Earnings Call Transcript March 26, 2025 Dyadic International, Inc. misses on earnings expectations. Reported EPS is $ ...

Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to acceler ...

近日，中国农业科学院兰州兽医研究所外寄生虫与虫媒疫病团队在非洲猪瘟病毒免疫抑制基因鉴定和宿主抗病毒分子的筛选方面取得了新的进展，相关研究以“The African swine fever virus gene MGF_360-4L inhibits ...

Good evening and welcome to Dyadic International's Year-End 2024 Conference Call. Currently, all participants are in a listen-only mode. Following management's prepared remarks, there will be a brief ...

导读Introduction系统性红斑狼疮(SLE)是一种慢性自身免疫性疾病，其发病机制复杂且部分尚未完全阐明，可导致广泛的临床表现和血清学异常。本文重点介绍了2024年SLE领域的重要研究进展，涵盖发病机制、生物标志物、新疗法和临床结局等方面。一、发病机制低密度中性粒细胞(LDNs)和血小板表达的Toll样受体7(TLR7)在SLE和狼疮肾 ...

DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic International Inc. (NASDAQ:DYAI) announced 2024 results and listed a number of accomplishments that will bring both product and grant revenue in the next ...